f94te rd9sa 5k2b5 5yidn 42y4b zbkk8 zt7ka a4eaf e6y68 nzs24 6rnnf sah5k fn6b4 7dtbe 4hakb 833nk rh462 9i2fd 9rt6t h4z55 5tb56 Marvel's Avengers | Avengers Day | Walkthrough #1 |

Marvel's Avengers | Avengers Day | Walkthrough #1

2021.12.01 10:34 CiubacaXD Marvel's Avengers | Avengers Day | Walkthrough #1

submitted by CiubacaXD to YoutubeGamingVidPromo [link] [comments]


2021.12.01 10:34 roham_kh007 😂 😂 😂 😂

😂 😂 😂 😂 submitted by roham_kh007 to keoXer [link] [comments]


2021.12.01 10:34 SocialFlotsam Just a Flesh Wound [JFW] has two openings!

We are an active, fun, and friendly clan focused on helping each other progress and enjoying our time in game.
We down Ultra, Nightmare, and Brutal daily
We stay competitive in CVC without being tyrants about it
Requirements:
Discord is a must! We do most of our planning and communication on Discord.
120k points in CvC.
3 Clan Quests a week.
4.5 mil player power
Please apply in game and be sure to include a message about yourself!
submitted by SocialFlotsam to RaidShadowLegends [link] [comments]


2021.12.01 10:34 aruaryana Can someone explain Bonnie and Enzo's love story to me?

Like why'd they get together. They were cute as a couple but I don't understand why Bonnie was so affected by his death and shit and why they got together in the first place lol
submitted by aruaryana to TheVampireDiaries [link] [comments]


2021.12.01 10:34 Weeklyn00b Is there a single time there's been two different characters talking not seperated by cuts?

Every IRL scene with multiple characters, there is always a cut between dialogues. That is Scott the Woz' trademark cinematographical style, and it's something I've gotten more concious about. Now I would like to place a bounty on finding a single time there's been two pieces of dialogue in 1 take, dead or alive. I am genuinely curious if he has been this consistent
submitted by Weeklyn00b to scottthewoz [link] [comments]


2021.12.01 10:34 burgerking_foot Indonesia Compared To Europe

Indonesia Compared To Europe submitted by burgerking_foot to MapPorn [link] [comments]


2021.12.01 10:34 cmstrump Why You’re Probably Better Off Buying Bitcoin Than Bitcoin Futures ETFs

submitted by cmstrump to btcmarkets [link] [comments]


2021.12.01 10:34 Myrandall Grapplesniper by Jay Axer

Grapplesniper by Jay Axer submitted by Myrandall to ImaginaryArchers [link] [comments]


2021.12.01 10:34 dinosaurancestry Monarch on a African daisy

Monarch on a African daisy submitted by dinosaurancestry to animalswithfood [link] [comments]


2021.12.01 10:34 Odd-Mountain3076 PVD with Class A and all endorsements including MT training

I applied for PVD right before truck driving school as a good fallback in case I didn't pass my road test. Well, I did and I was already getting a ton of calls and was onboarded to be a PVD 2 days after I finished. So a PVD now and already have two non-UPS jobs lined up after Jan 15 when PVDs are pulled. The idea of feeder was proposed..but I really do enjoy the PVD work right now as it's low key and easy now that I've memorized my route. I keep my head low and do my job.
I would like to still drive for UPS and I would imagine the fact I can drive anything would help my chances. That said the facility I am working at now won't work as I am leaving the area in April and moving to Maine to help care for my aging parents. I am thinking about emailing the Maine folks and introducing myself to perhaps get put on PT or ? once I get up there. At least get my name known for future opportunities. Should I mention to my sup for an introduction as well?
Thoughts?.
submitted by Odd-Mountain3076 to UPSers [link] [comments]


2021.12.01 10:34 laxyharpseal When you just want to farm threads but you become a weirdo who strips zombie naked

When you just want to farm threads but you become a weirdo who strips zombie naked submitted by laxyharpseal to projectzomboid [link] [comments]


2021.12.01 10:34 Memer6969-3000 This now my new favorite Doomguy matchup. Doomguy vs Dante (DOOM vs Devil May Cry)

This now my new favorite Doomguy matchup. Doomguy vs Dante (DOOM vs Devil May Cry) submitted by Memer6969-3000 to DeathBattleMatchups [link] [comments]


2021.12.01 10:34 Thick_Engine_8928 Drs 2nd time round

Does this just match up with my existing Computershare account? Anybody else done 2 transfers?
submitted by Thick_Engine_8928 to NZGME [link] [comments]


2021.12.01 10:34 Dontrespondcrybaby Money Maker? 💰

View Poll
submitted by Dontrespondcrybaby to Shortsqueeze [link] [comments]


2021.12.01 10:34 Good-Plane-1020 Just Fair-launched!🚀 A Tidal Wave 🌊 of Profits to 🔱Aqua Shiba's investors! Join the Heroic Aqua Shiba on his heroic crusade to save the Crypto & Defi World! Join our Royal Atlantian Army as we embark on our campaign to become the #1 DeFi Token in all of Crypto. Join the Hero Company!

Just Fair-launched!🚀 A Tidal Wave 🌊 of Profits to 🔱Aqua Shiba's investors! Join the Heroic Aqua Shiba on his heroic crusade to save the Crypto & Defi World! Join our Royal Atlantian Army as we embark on our campaign to become the #1 DeFi Token in all of Crypto. Join 🔱Aqua Shiba Today.
🔱Aqua Shiba just Launched🚀 from depths of the Majestic Ocean and bringing a Tidal Wave 🌊 of Profits to his investors! Lets do this lets get this cheddar! Lets Go!
🌐Website: https://www.aquashiba.cc
📱Telegram: https://t.me/AquaShibaCoin
🐤Twitter: https://twitter.com/AquaShibaCoin
🌐BSC Scan: https://bscscan.com/token/0x37B8996C92f9143aE82183280b120a3499Ab0b3C
Liquidity is locked: https://deeplock.io/lock/0xabAF6f50Ac9219B9E19e35D97773294Aa6141e10
Contract Ownership is Renounced: https://bscscan.com/tx/0xb7604d35e9873e076060b4f87d6ce70df13e039e84fd0106a0e227d95ad0187a
📝Contract: 0x37B8996C92f9143aE82183280b120a3499Ab0b3C
Buy with 11% Slippage right here on PancakeSwap!
Aqua Shiba has assembled his greatest generals to form the Royal Atlantian Marketing Council to market our token far and wide by advertising via multiple avenues such as Reddit, Twitter, Facebook, Token Listing sites, and much more.
The Bounties of Aqua Shiba's Heroic Campaign will be shared with all his loyal hodlers via Heroic Reflection Rewards, Token Airdrops and Community Awards and Prizes.
Our Tokenomics are as follows:
Auto-Liquidity: All Aqua Shiba transactions contribute 7% to our liquidity pool ensuring price stability, sustainable growth for all his Aqua Shiba investors. Multiple liquidity pools and stable coins parings with BUSD & USDC will be added as our community grows.
Safe & Secure: Aqua Shiba puts the safety and security of his Army as his top priority and has ordered that Contract Ownership be Renounced at launch & 100% of Liquidity be Locked, therefore, ensuring that his token is decentralized and no individual, group, or entity has control over his royal token and ensuring safety and security for all his investors.
Heroic Reflections: All Aqua Shiba holders will observe their token balance grow through Reflection Rewards at intervals as the community grows. This function will allow holders to effectively earn interest over time and will scale as the community grows.
Heroic Marketing: Aqua Shiba has formed the Royal Atlantian Marketing Council which will utilize the Royal Atlantian Treasury of which 3% of every transaction is contributed to launch a Marketing Campaign covering multiple avenues such as Reddit, Twitter, Facebook, Token Listing sites, and much more. Aqua Shiba is going to save the entire crypto world and rain riches down on his loyal soldiers!
submitted by Good-Plane-1020 to CryptoMars [link] [comments]


2021.12.01 10:34 Ella_Elly Buying kawaii demon horn (something like that

Ia:1k
submitted by Ella_Elly to RoyaleHighTrading [link] [comments]


2021.12.01 10:34 KingShahar Hey! Look at me.

Hey! Look at me. submitted by KingShahar to clevercomebacks [link] [comments]


2021.12.01 10:34 jvermorel Copycats in Supply Chain (20min video)

Imitation is said to be the sincerest form of flattery. A semi-serious supply chain discussion from the perspective of an enterprise software vendor : https://www.youtube.com/watch?v=1xwxQbJRa8A
Cheers, Joannes
submitted by jvermorel to supplychain [link] [comments]


2021.12.01 10:34 unbreakablesausage Review #350: Glenlossie 1998 Gordon & MacPhail

Review #350: Glenlossie 1998 Gordon & MacPhail submitted by unbreakablesausage to Scotch [link] [comments]


2021.12.01 10:34 Riverjr125-3 So I recently found out the way to get a pattern on your hhp profile. All you gotta do is visit houses. I don’t know the amount but Wardell will give you different dialogue. After leaving the tour the first pattern you will get is polka dots.

submitted by Riverjr125-3 to AnimalCrossing [link] [comments]


2021.12.01 10:34 JesseBBrown Bizarre Things That Have Been Banned Around the World

Bizarre Things That Have Been Banned Around the World submitted by JesseBBrown to Thatsnotpossible [link] [comments]


2021.12.01 10:34 Mkovich92 Anyone else HAD to take this pic?

Anyone else HAD to take this pic? submitted by Mkovich92 to AnimalCrossing [link] [comments]


2021.12.01 10:34 ReginaldKray33 München: Fliegerbombe in Nähe der Donnersbergerbrücke explodiert

München: Fliegerbombe in Nähe der Donnersbergerbrücke explodiert submitted by ReginaldKray33 to de [link] [comments]


2021.12.01 10:34 CryptoBumGuy Get Lucky ASA: 415326737 - No Loss Lottery starts TODAY! Hold the Luck token to participate. The more you hold means the bigger the donation to fight climate change.

www.GetLuckyASA.com
GetLuckyASA
You feeling lucky?
submitted by CryptoBumGuy to AlgorandAirdrops [link] [comments]


2021.12.01 10:34 ny92 $NVCT – The definition of a boom / bust squeeze play – mixed with some spicy IPO action for a catalyst.

Morning y’all, hope you’ve been keeping well and your ports even better. This post isn’t as detailed nor company oriented as my typical DDs because it’s more to do with the external environment around the company given the context of what’s been happening with ‘squeezes’ over the past couple of weeks than the company itself, although the low float and low market cap element should play a key role if this does take off. FYI The IPO is today, 12/1
Before I go into the details, please note that nothing in this post should be considered financial advice so please don’t treat it as such – do your own due diligence, read the news to understand the macroeconomic environment and the Company’s position in the industry, study their financials as well as reading what others are saying/reviewing to help you make an informed decision before making any investment if you choose to do so.
Part 1 – Context
Part 2 – Company Overview
Part 3 – Financials
Part 4 – Squeeze Potential
Part 5 – Bear Case
Part 6 – TL;DR
Part 1 – Context
The potential for this to turn into a play came about due to a convergence of two elements I’ve been loosely tracking recently – the first being relatively bullish momentum around IPOs from a couple weeks back, with SEV – a potential solar car manufacturer - showing up on my scanner due to unusual volume flow just prior to its first halt when EVs were popping off led by RIVN and LCID. The multiple halts and buying frenzy seemed a bit extreme given some of the details that jumped out when I read their SEC filings, with the following highlights in their own words link:

We will have to raise additional funds until the start of the production of the Sion and potentially beyond, which may not be available to us on acceptable terms or at all when we need them. According to our current estimates, we currently expect to need funds in the total amount of at least €354 million between September 2021 and the start of the production of the Sion, which we currently envisage to begin in the first half of 2023 (based on soft tooling production to be subsequently replaced by hard tooling)
We depend on National Electric Vehicle Sweden (NEVS) for production of the Sion. In 2020, NEVS was acquired by a Chinese enterprise, Evergrande. Recent events, such as failure to pay interest on outstanding indebtedness on its due date, suggested that Evergrande faces liquidity challenges. These challenges will likely negatively affect NEVS, and could lead to a sale of NEVS by Evergrande. We may be forced to renegotiate our arrangements with NEVS or to search for a new manufacturer.’
Despite the fact that this company is nowhere near production with respect to timeline and tooling, is reliant on a borderline bankrupt entity for manufacturing their vehicles, and is going to need to raise more cash before it can make it to production, the momentum of being linked to EVs due to its solar powered vehicles and volume coming in on IPO day seem to have been enough to triple the market cap of SEV from the $15 per share they were looking for to a high of $47.49, making it a $3B company for a short while before bleeding back down to the IPO price approximately a week later.
A couple of healthcare stocks popped around this time as well, not IPO related but still squeezing somewhat – the main two being LGVN and ISPC which were multi-day runners that turned out to be a 20x and a 5x respectively if you got in earlier this month. The price action around healthcare related stocks got me curious about whether there could be a sector related play for AERC, a stock which showed up on the list of upcoming IPOs at the time that was sandwiched between two SPACS. I read the brief on Nasdaq’s website but like SEV ended up not considering it a worthwhile investment, with some of their key highlights (in their own words) being link:
Although we have raised approximately $15 million thus far, if we are unable to continue to raise additional funds to support our growth, there would be substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing. We have no commitments for future financings, and we anticipate that we will require additional funding over the next several years in order to continue our efforts to develop and commercialize our products.
We do not yet have full FDA clearance to market our products in the United States.
Our products have not been proven to reduce the risk of COVID-19 transmission. While we have proven that our devices can eliminate 99.99% (4 Log) of airborne pathogens in controlled laboratory environments, including a pathogen that is a surrogate for COVID-19, we have not conducted any tests or studies regarding the ability of such devices to reduce the spread of COVID-19 and any mutation or variation thereof, and our devices may ultimately not succeed in reducing the spread of COVID-19 or any mutation or variation thereof.
Our business strategy depends largely on our ability to sell our products to hospitals and other healthcare facilities. We have limited experience with respect to sales and marketing, and in particular marketing to hospitals and healthcare facilities.
Despite the fact that this company is pre-revenue and to the best of my understanding not really offering a revolutionary product (not an air purification specialist so anyone who has a background in this please feel to correct me and I’ll update), does not have the experience nor established market to sell its product to, has not tested its signature product on arguably the key virus that it seeks to eradicate, and has substantial doubt about its ability to survive without additional funding rounds, apparently it was enough to rocket the listing price of $10 to opening at ~$40 and reaching a high of $117.35. This in effect propelled the $25m offering (2.5m share float) to $293.1m, with an overall company valuation increase from $138.6m to $1,626.9m.
Following the IPO, I was thinking that there was clearly something really special about the tech that I misunderstood and more importantly that led the underwriters to misprice the IPO by a magnitude of 10+ (lol), but yesterday the price tanked to $14.31 from $108.04 so this made even less sense. I don’t believe the company did anything special in the week or two prior to the IPO to cause it to 10x, nor did I find any news to explain what they did that was so terrible that it caused their SP to fall off a cliff by 85% the following week – which increased my ‘confidence’ for lack of a better word that this was probably a momentum play that just got dumped. If anything, the SP should’ve risen further with the news of the Omicron variant since theoretically that’s what the company’s device should help protect individuals against.
Over the last couple of weeks, and last few days especially, a variety of healthcare related stocks have ‘squeezed’ for lack of a better term, on an almost whack-a-mole basis, with some of these names including the two mentioned earlier in LGVN and ISPC, as well as PTPI, PRPO, QLGN, CNTX, in addition to other low float stocks such as PPSI, NUZE, etc.
When you combine the majority of the ingredients to what I perceive were key to these companies’ success (at least with respect to the SP in the short-run) including IPO-ing, healthcare-related, low float, low market cap etc (missing SI but some cases like ISPC, PRPO, CNTX there was also minimal to negligent SI), I believe you have the potential recipe for a multi-bagger in NVCT (well, at least this was my theory before the market dumped hard for most of the last week so we’ll see if it’s right or wrong later today). Before we get into those numbers for NVCT, let’s take a quick look at the company even though judging by how SEV and AERC did – the merits don’t really seem to matter as much as momentum and float (disclaimer – I know virtually nothing about this sector, the TAM or the usefulness of the products for which the company’s aiming to start trials so if you have any insight please let me know and I’ll add it here).
Part 2 – Company Overview
The following is a brief taken primarily from the SEC filings and the company’s website, it’s pretty much all in their own words since I don’t want to attempt summarizing technical details pertaining to pharma and get it wrong since it isn’t an area that I have a background in or much exposure to.
Nuvectis Pharma, Inc is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious unmet medical needs in oncology. They rely on their core competencies of target selection, drug profiling, and clinical and regulatory execution to build a pipeline of anticancer targeted-therapy drugs. Improved genetic sequencing and understanding of cancers’ RNA, DNA and protein abnormalities has led to the discovery and characterization of novel oncogenic genetic mutations and alterations that were previously unknown, unaddressed, unsuccessfully targeted or overlooked. They believe that these advancements represent a fundamental change in the development of targeted therapies and will increasingly lead to tumor agnostic approaches whereby cancers will be characterized for treatment based on genetic signatures, such as a certain mutation, rather than in a tissue-specific manner. They are currently developing two preclinical drug candidates with the lead candidate expected to begin a Phase 1 clinical trial in the fourth quarter of 2021.
With their precision medicine approach, they aim to pharmacologically target novel oncogenic pathways which are key drivers of the disease. As such, they believe that their approach can also enable the use of biomarker-based patient selection, wherein patients are selected for treatment with a drug based on specific attributes of their cancer, such as specific mutations and cellular alterations, and could prospectively identify patients that are more likely to benefit from their targeted therapy, a type of cancer treatment that precisely identifies and attacks a specific pathway of cancer cells, thereby potentially increasing the likelihood of a successful treatment outcome. They have extensive experience and expertise in licensing promising product candidates from a wide range of global sources, including universities, academic/research centers and biotechnology companies.
In May 2021, they licensed exclusive worldwide commercial rights to NXP800, an HSF1 pathway inhibitor, their lead product candidate, which was discovered and developed in the drug discovery program at the Institute for Cancer Research (“ICR”) in London, England. The ICR performs pioneering work in discovering new cancer drugs with unique mechanisms of action. The ICR’s drug discovery unit has discovered several successful clinical drug candidates, the most notable of which is Zytiga, a leading drug for metastatic prostate cancer. In August 2021, they licensed worldwide commercial rights to NXP900, a novel SRC/YES1 kinase inhibitor from the University of Edinburgh, Scotland, U.K. (“UoE”). UoE is considered a leader in research designed to discover novel targeted-therapy drug candidates link.
A summary of their two pipeline candidates is link:
NXP800 – an oral small molecule inhibitor of the HSF1 pathway
Licensed from the Institute for Cancer Research (ICR) in England Initial target indications: ovarian clear cell carcinoma (OCCC) and advanced-stage endometrioid ovarian cancer Their Phase 1 trial of NXP800 in advanced solid tumors is planned to begin in 4Q2021
NXP900 – an oral small molecule SRC/YES1 kinase inhibitor with a differentiated mechanism of target inhibition
Licensed from the University of Edinburgh in Scotland Differentiated mechanism of action and target selectivity provide an opportunity for development in solid tumors Preclinical development of NXP900 to enable first-in-human clinical study ongoing
The pipeline can be viewed illustratively here link
The leadership team consists of three co-founders who have a proven track record of successful drug development and capability to raise the capital necessary to support the development of product candidates. Collectively, they held leadership roles in companies that achieved four U.S. FDA approvals and launches of novel medications in both oncologic and non-oncologic indications, including three New Drug Applications (“NDAs”) and one Biologics License Application (“BLA”), as well as two approvals in the European Union (“EU”), and one approval in Japan (via a Japanese partner).
Their co-founders successfully led the approvals and launches of: Auryxia®, which is approved for the treatment of hyperphosphatemia in patients with dialysis-dependent chronic kidney disease (“CKD”) and for the treatment of anemia in patients with non-dialysis-dependent CKD; Jelmyto®, which is approved for the treatment of upper tract urothelial carcinoma; and Elzonris®, which is approved for the treatment of blastic plasmacytoid dendritic cell neoplasm. Notably, significant regulatory achievements of their leadership team also include obtaining two Breakthrough Therapy Designations in oncology and six Orphan Drug (four U.S. and two EU) and two Fast Track Designations.
More information on the team and the prospectus can be viewed here link
Part 3 – Financials
Their financials aren’t particularly pretty but then again I’ve never really seen an early-stage biotech’s that are, there also isn’t much to really analyze so I’ll just leave the key points up for you to take a look:
Net loss for the period of nine months ending as of September 30th, 2021 was $10.6m
Cash and cash equivalents on September 30th, 2021 was $6.8m
They estimate that the net proceeds to them from the offering will be approximately $25,787,800, or approximately $29,846,725 if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $13.00 per share
Part 4 – Squeeze Potential
The 2021 IPO scorecard from iposcoop link has the number of IPOs priced at 431, with 191 up, 238 down and 2 unchanged i.e. 44.3% or less than half overall have actually provided investors with positive returns for the year, with total return from issue price averaging out to 5.57% which is approximately a quarter of the Nasdaq Composite Index YTD & Change of 20.20%. However, when we look at recent data i.e. the last 100 IPOs, we see 59 up, 40 down and 1 unchanged so i.e. 59% have led to positive returns with respect to share price appreciation which is 15% higher than the total for the overall year, and the percentage change from the issue price at 8.83% compared to 2.18% for the Nasdaq Composite, which is approximately 4x of the Nasdaq Composite. So while the year as a whole can be perceived as IPOs being more likely than not to be a negative investment, it seems that most of the negative ones occurred earlier in the year since the overall percentage vs the Nasdaq went from being ¼x to 4x when compared to recent data. Effectively if you’re throwing a dart at a board now vs. earlier in the year the likelihood of NVCT taking off vs sinking (at least initially) is higher compared to the overall year.
In November alone, out of 34 IPOs (a couple like AERC aren’t on the list due to recency and a couple data points were omitted for not being present) 17 had positive returns and 17 had negative returns till date of reporting which is 50% either way so not great overall but still higher for the overall year. However, if you look at the shorter timeframe in which this play is expected to occur over i.e. day or two not weeks/months, then you see the first day difference was net positive for 23, negative for 9, and neutral for 2, meaning almost ~68% would still have got you returns on D1 if you got in near the IPO price. In the last 100 days out of 22 healthcare related IPOs, 16 were positive at EOD on the first day compared with 6 negative meaning ~73% would’ve netted you positive returns on the first day.
Now looking at recent squeezes, here’s a non-exhaustive list I’ve observed (float ranges are from floatchecker except where specified):
LGVN – 2.69m to 3.29m float, ~502m current MC
ISPC – 2.4m to 5.23m, ~129m current MC
PTPI - 4.4m to 8.05m float, ~38m current MC
PRPO - 21.85m to 22.0m float, ~44m current MC
QLGN - 25.8m to 28.89m float, ~43m current MC
CNTX - 0.28m to 10.0m float this company has data all over the place so here’s a link to see for yourself, not the most reliable – personally I would go with 5.75m as that’s the IPO’d number of shares link , ~79m MC going off the 10.2m shares outstanding filed within their prospectus and S1 [link 1])(https://www.sec.gov/Archives/edgadata/0001842952/000119312521303138/d46596d424b4.htm), link 2
PPSI - 3.79m to 4.02m float, ~88m current MC
NUZE – 11.5m to 12.42m float, ~83m current MC
If we look at the commonalities - all have low floats or low market caps, with decent short interest present in LGVN and PPSI prior to their squeeze and QLGN during/post squeeze – indicating that high SI is not a critical element for the success of these recent squeezes, as they seem to occur predominantly due to their float/low market cap or a combination of both mixed with somewhat of a catalyst in certain cases.
If we look at NVCT specifically, the offering is expected to be for 2.3m shares (2.65m if underwriters pickup the additional 345k stock they have been offered within 45 days) at a share price from a range of $12-$14. This leads to a float valuation ranging from 29.9m to 34.5m using the midpoint of $13 as NVCT has done in their S-1 filing link while having ~13.9m – ~14.2m shares outstanding link which would’ve valued the company at ~$139m to $142m (also similar to NVCT). As it turns out the price hit $117.35 which propelled the $25m offering to $293.1m, with an overall company valuation increase from $138.6m to $1,626.9m.
Part 5 – Bear Case
As far as the bear case goes, I’ll be the first to admit that my expectation that this could pop is based on conjecture and a loose connecting of the dots/finding a pattern based on some research and sprinkled with some anecdotal observations. I’m reiterating that the information here is thinner on numbers than I am typically accustomed to, with the main numbers here just being the tiny float up for sale (2.3m-2.65m), the SP (12-14) and the resulting float value of ($27.6m – $37.1m). I’m not in this for the long-run and I don’t see myself playing it past a day or perhaps longer if it goes similar to AERC, but in the interest of trying to paint a whole picture (as I’ve attempted to do throughout this document), please see below some additional bearish factors, and I’m sure more can be found here link:
The following clauses aren’t the most reassuring if you’re aiming to be a long-term investor ‘We are very early in our development efforts and are substantially dependent on our lead product candidate, NXP800. If we are unable to advance NXP800, NXP900 or any of our other future product candidates through clinical development, obtain regulatory approval and ultimately commercialize NXP800, NXP900 or any of our other future product candidates, or experience significant delays in doing so, our business will be materially harmed. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization of NXP800 or future product candidates.’
The early-stage nature of the product pipeline and the minimal resources they have means that it’s pretty much an all-or-nothing approach towards their lead candidate and if that doesn’t work out then they’re going to have significant issues down the line.
Furthermore, the company expects to raise ~$26m from the cash offering, if we extrapolate the $10.6m burn rate in 3Q to a full year that’s ~$14m, meaning the capital they’re raising from the IPO won’t make it through a full two years, even less if they end up onboarding more resources/increasing the burn rate without having a further offering since it’s unlikely they’ll have the revenue to acquire debt and pay the interest back within those couple of years due to a probable lack of product. They’re also paid licensing fees for their product candidates and that impact would need to be evaluated down the line as well.
Part 6 – TL; DR
Nuvectis Pharma is a pre-revenue biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Their current product pipeline consists of two products - in May 2021, they licensed exclusive worldwide commercial rights to NXP800, an HSF1 pathway inhibitor, their lead product candidate, which was discovered and developed in the drug discovery program at the Institute for Cancer Research (“ICR”) in London, England. The ICR performs pioneering work in discovering new cancer drugs with unique mechanisms of action. The ICR’s drug discovery unit has discovered several successful clinical drug candidates, the most notable of which is Zytiga, a leading drug for metastatic prostate cancer. In August 2021, they licensed worldwide commercial rights to NXP900, a novel SRC/YES1 kinase inhibitor from the University of Edinburgh, Scotland, U.K. (“UoE”). UoE is considered a leader in research designed to discover novel targeted-therapy drug candidates.
The leadership team consists of three co-founders who have a proven track record of successful drug development and capability to raise the capital necessary to support the development of product candidates. Collectively, they held leadership roles in companies that achieved four U.S. FDA approvals and launches of novel medications in both oncologic and non-oncologic indications, including three New Drug Applications (“NDAs”) and one Biologics License Application (“BLA”), as well as two approvals in the European Union (“EU”), and one approval in Japan (via a Japanese partner).
The company expects to raise ~$26m from the cash offering of 2.3m shares at an average of $13, providing it the capital to fund operations through ~2 years at the current burn rate. It is an early-stage pharma company and does not expect to recognize revenues in the short-run leading to the possibility of another offering being needed prior to being at a stage where their product(s) are in the market and they are able to recognize revenue.
Recent IPOs are more likely than not to result in positive share price appreciation, with this being true especially for an entry and exit during the first day, and even more-so when looking at healthcare related stocks. Add in the fact that some institutions/funds may picking up some of the float as long term holds [link] https://kalkinemedia.com/us/news/ipo/nuvectis-pharma-nvct-ipo-how-to-buy-the-stock) and the fact that multiple recent healthcare related low float/low market caps have been squeezing over the last week creates a potential opportunity for NVCT to have a multi-bagger squeeze on its big day.
Let me conclude by emphasizing once again that this is a higher risk/reward play than the other plays I have written about (there is literally no floor or resistance so this could be extremely volatile prior to stabilizing) which were mostly either to do with beaten down value plays e.g. GOEV or time-sensitive windows such as BKSY during the earlier de-SPAC phenomena. If this company were already IPO’d and in a different sector I would not be looking to invest in it at this moment in time, as admirable as its intended solutions are and the TAM they could address because there’s a whole bunch of revenue generating, lower risk-investments you could make that would likely provide you with a better return in the short-medium turn, especially given the recent turbulence in the market.
submitted by ny92 to SqueezePlays [link] [comments]


http://sparta-s.ru